Clinical trial • Phase III • Oncology|Other

Clinical trial in Vulvar cancer | Vulval cancer

Phase III trial for Vulvar cancer | Vulval cancer. 24 participants.

Overview

Trial Therapeutic Area
Oncology|Other
Trial Disease
Vulvar cancer | Vulval cancer
Trial Stage
Phase III

Key dates

Initial CTIS Submission Date
16-05-2025
First CTIS Authorization Date
14-08-2025

Trial design

Phase III trial across 2 sites in Netherlands.

Target Sample Size
24

Eligibility

Recruits 24 Vulnerable population selected (isVulnerablePopulationSelected: true). The trial population is female only; no details on consent/assent handling provided..

Vulnerable Population
Vulnerable population selected (isVulnerablePopulationSelected: true). The trial population is female only; no details on consent/assent handling provided.

Recruitment

Planned Sample Size
24
Recruitment Window Months
24

Geography

Total Number Of Sites
2
Total Number Of Participants
24

Netherlands

Earliest CTIS Part Ii Submission Date
22-07-2025
Latest Decision Or Authorization Date
14-08-2025
Processing Time Days
23
Number Of Sites
2
Number Of Participants
24

Sites

Site Name
Amsterdam UMC Stichting
Department Name
Verloskunde & Gynaecologie
Contact Person Name
Stijn Mom
Contact Person Email
c.mom@amsterdamumc.nl
Site Name
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Department Name
Gynaecologie
Contact Person Name
Teska Schuurman
Contact Person Email
t.schuurman@nki.nl

Sponsor

Primary sponsor

Full Name
Amsterdam UMC Stichting
Organisation Type
Patient organisation/association
Country Of Registered Address
Netherlands

Related trials

Other published trials that may interest you.